Spondyloarthritis & psoriatic arthritis
Evolving Economic Burden of Spondyloarthritis (2015–2023): A Nationwide Analysis of Direct and Indirect Costs
Authors' conclusion
Despite major therapeutic advances, the economic burden of SpA in France increased substantially between 2015 and 2023, driven by rising outpatient, medication-related, and indirect costs.
Study context
- Population
- Patients with spondyloarthritis (SpA), including psoriatic arthritis (PsA), in France, 2015–2023identified in 2023
- Participants
- 270,290 patients
- Outcome
- Temporal changes in direct and indirect economic burden of SpA/PsA
- Follow-up
- 2015–2023
Methodological detailsnationwide, French National Health Data System (SNDS), validated administrative algorithms
- Nationwide
- French National Health Data System (SNDS)
- Validated administrative algorithms
Main finding
As reported in the abstract
Economic burden of SpA/PsA (total reimbursed expenditures), France
Total reimbursed expenditures, 2023
euro1.19 billion
Increase in number of patients, 2015–2023
45.1%
Increase in total expenditures, 2015–2023
52.2%
Increase in indirect costs, 2015–2023
78.5%
Observational data: associations, not effects.
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Evolving Economic Burden of Spondyloarthritis (2015–2023): A Nationwide Analysis of Direct and Indirect Costs. Joint Bone Spine. Published 17 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →